The first developed anti-HER2 ADC was trastuzumab emtansine (TDM-1), which showed promising preclinical data in vitro and in vivo, though clinical results for solid tumors other than breast cancer have been more disappointing [20]. This evidence concerns the gene ERBB2 and breast carcinoma.